CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
CytoTrack has developed a technology to identify and isolate metastatic cancer cells from blood samples. This innovation aims to improve personalized cancer treatment by enabling precise characterization of these cells, potentially reducing cancer-related deaths and healthcare costs.
ChallengeUp to 40% of patients diagnosed with metastasised breast cancer fail to respond to treatment.
Cancer cost the EU €126bn in 2009 incl. productivity losses of €42.6bn and lost working days worth €9.43bn. 3.2m citizens in EU lose their lives to cancer each year.SolutionCirculating Tumour Cells (CTC) are cells that have shed into the vasculature from a primary tumour and circulate in the bloodstream.
CytoTrack has developed a breakthrough technology that can identify and isolate metastatic…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
